Dear Editor, Slow-flow vascular malformations (VMs), particularly venous VMs, might get complicated by intramalformative thrombosis linked to localized intravascular coagulopathy (LIC).
1–3 Several studies have shown the effectiveness of sirolimus on slow-flow VMs but its effect on coagulation has been poorly studied.
3 Moreover, vascular endothelial growth factor (VEGF) A and C are known for their proangiogenic and lymphangiogenic activities, respectively, and sirolimus may reduce their levels.
4 In this study, we investigated blood levels of VEGF-A and -C, tissue factor (TF) and coagulation markers in children with slow-flow VMs before and after sirolimus treatment. The protocol was approved by the institutional review board of the University Hospital Centre of Tours (#2015-R18) and received authorization from Agence Nationale de Sécurité du Médicament et des produits de santé. The data may be shared on reasonable request (submitted to dpo@chu-tours.fr).